Analyst Cuts Valeant Pharmaceuticals As Bill Ackman "Throws In The Towel"

Posted March 15, 2017

These analysts have also projected a Low Estimate of $0.38/share and a High Estimate of $1.32/share. (NYSE:VRX) puts the stock on today's active list. (NYSE:VRX) shares have moved -11.1470%.

Analysts from BMO think the sale by Bill Ackman is bad news for Valeant Pharmaceuticals shareholders.

Meanwhile, the SEC filings show that Susquehanna International Group acquired 2.56 million shares of Valeant during the fourth quarter. US Bancorp DE increased its position in shares of Valeant Pharmaceuticals Intl by 141.0% in the third quarter. Valeant was trading after hours Monday at $10.91, down 10 percent. The firm's 50 day moving average price is $14.30 and its 200-day moving average price is $18.77.

Shares of Valeant Pharmaceuticals Intl (NYSE:VRX) opened at 12.24 on Tuesday. The difference between the expected and actual EPS was $0.05/share, which represents an Earnings surprise of 4.1%.

Revenues in the quarter fell 13% to $2.4 billion, versus $2.8 billion in the same quarter of 2015. Pershing sold its remaining stock in recent weeks for an average of US$11 per share, having originally paid an average of US$196 per share in early 2015. In October 2015, short-seller Andrew Left of Citron Research alleged Valeant and Philidor, a mail-order pharmacy and one of its customers, had engaged in a secret relationship to improperly hike revenues.

Last month, Valeant reported financial results for the fourth quarter and for the full-year 2016.

'Not thinking of alliance with anyone': BSP sources
When asked if he was willing to form an alliance with the BSP after the results were out, Yadav said, "Yes, if the need arises". Singh told News18, that Rahul Gandhi and Akhilesh Yadav neither had any issue nor any concrete plan for the elections.

Digging a bit further, company shares have been noted -84.79% off the 52 week high and -5.72% away from the 52 week low.

ValueAct Holdings, managed by Jeffrey Ubben, reported holding 14.99 million shares at the end of the past year.

While that would still leave the company with a debt load totaling more than five times its current sub-$5-billion market value, Rodman & Renshaw senior healthcare Analyst Ram Selvaraju told BNN on Tuesday there is no "immediate-term risk" of bankruptcy.

Many analysts have provided their estimated foresights on Valeant Pharmaceuticals International, Inc.

The company's growth for the past 5 years has been at 12.66 percent. The ratio is below acceptable minimum levels, indicating that the company's ability to conduct transactions, such as acquisitions, is restricted, and it's dangerously close to default levels. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).